- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Roche Shuffle Keeps Focus on Personalized Care
The departure of Pascal Soriot from Roche’s pharmaceutical division to the helm of rival AstraZeneca comes as a surprise, but the move isn’t likely to leave a hole among the higher ranks of the Swiss drug maker.
Roche veteran Daniel O’Day, who was tapped to replace Mr. Soriot as the new head of the Roche’s flagship pharmaceutical division, is well-equipped for the job. He’s held various positions at the unit since 1987 and spent his entire career at Roche, including postings in the U.S. and Japan. Most recently, Mr. O’Day, an American national, spent six years at Roche’s diagnostics division, leading it as chief operating officer since 2010.
Read the full story: http://tinyurl.com/9e2z5px
Source: The Wall Street Journal
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Unique Psychological Burden of Fear of Progression Seen in MG
August 6th 2025Fear of progression is common among patients living with chronic diseases, but the degree to which it interferes with patient outcomes, including treatment adherence, deserves further investigation, study authors note.
Read More
